|
|
Clinical study of Huoluo Tongbi Pills combined with Methotrexate in the treatment of rheumatoid arthritis |
LI Ting ZHENG Baolin YE Meixing HUANG Yanhua CHEN Junli LIANG Jianliang |
Department of Rheumatology, Foshan Hospital of Traditional Chinese Medicine, Guangdong Province, Foshan 528000, China |
|
|
Abstract Objective To explore clinical efficacy of Huoluo Tongbi Pills combined with Methotrexate in the treatment of rheumatoid arthritis (RA). Methods Eighty-five patients with RA admitted to Foshan Hospital of Traditional Chinese Medicine from January 2017 to December 2018 were divided into control group (43 cases) and observation group (42 cases) according to the random number table method. Control group was treated with Methotrexate, while observation group was treated with Huoluo Tongbi Pills combined with Methotrexate. Two groups were treated for 12 weeks. Clinical efficacy was evaluated after treatment. The joint swelling number, joint tenderness number, morning stiffness times and hands grip strengths were compared between two groups. The levels of rheumatoid factors (RF), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), matrix metalloproteinase-1 (MMP-1) and matrix metalloproteinase-3 (MMP-3) of two groups were compared before and after treatment. The adverse reactions of two groups during treatment were compared. Results Total effective rate of observation group was significantly higher than that of control group, the difference was statistically significant (P < 0.05). After treatment, the number of joint swelling and joint tenderness in two groups were less than those before treatment, the time of morning stiffness was shorter than that before treatment, and the hand grip strength was higher than that before treatment (P < 0.05); the improvement of the above indexes in observation group was better than that in control group (P < 0.05). After treatment, the levels of RF, ESR and CRP in two groups were significantly lower than those before treatment (P < 0.05), and those in observation group were lower than those in control group (P < 0.05). The levels of MMP-1 and MMP-3 in two groups after treatment were significantly lower than those before treatment (P < 0.05), and the level in observation group was significantly lower than that in control group (P < 0.05). During treatment, there was no serious adverse reactions of two groups. Conclusion Huoluo Tongbi Pills combined with Methotrexate in the treatment of RA has a good efficacy, it can improve the clinical symptoms, reduce the serum levels of MMP-1 and MMP-3, and has good safety.
|
|
|
|
|
[1] 翁志文,田贵华,陈荷清,等.中医按摩与汗蒸疗法治疗类风湿关节炎1例[J].国际中医中药杂志,2019,41(12):1398-1400.
[2] 朱丽芳,李伟,俸一然,等.类风湿关节炎患者366例临床病例分析[J].风湿病与关节炎,2018,7(5):34-37,44.
[3] 和雅,王燕,卢华清,等.甲氨蝶呤加雷公藤多甙片对类风湿关节炎的效果对比研究[J].泰山医学院学报,2019, 40(10):775-776.
[4] 闫俊,柴旭兵,贺冬冬,等.活血通痹膏外用联合特定电磁波治疗仪治疗类风湿关节炎痰瘀痹阻型临床研究[J].河北中医,2019,41(8):1202-1206.
[5] 宋万雄,宋林萱.活络通痹汤治疗类风湿性关节炎的临床疗效观察[J].中国现代药物应用,2017,11(19):131-132.
[6] Aletaha D,Neogi T,Silman AJ,et al. 2010 Rheumatoid arthritis classification criteria:an American College of Rheumatology/European League Against Rheumatism collaborative initiative [J]. Ann Rheum,2010,62(9):2569-2581.
[7] 国家中医药管理局.中医病证诊断疗效标准[S].南京:南京大学出版社,1994:129-137.
[8] 风湿免疫疾病慢病管理全国护理协作组.类风湿关节炎患者的慢病管理专家共识(2014版)[J].中华风湿病学杂志,2016,20(2):127-131.
[9] 韩海燕,沈敬华.类风湿关节炎发病机制的研究进展[J].世界最新医学信息文摘,2019,19(93):66-67,69.
[10] 刘志队,史丽璞,郇稳,等.中西药合用治疗类风湿性关节炎临床观察[J].实用中医药杂志,2019,35(9):1086-1087.
[11] 王康惠.四妙散加味治疗类风湿关节炎的临床疗效观察[J].中国医药科学,2018,8(21):54-56.
[12] 王梦娟,吴美娟.运动疗法在类风湿关节炎受累关节中的应用进展[J].中国现代医生,2018,56(35):164-168.
[13] 肖洁,万瑶.甲氨蝶呤片联合针灸治疗类风湿性关节炎临床效果研究[J].现代医药卫生,2019,35(20):3149-3154.
[14] 庄铭城,王小燕,陈培嘉.雷公藤多甙片联合甲氨喋呤治疗类风湿关节炎的临床疗效及对炎症因子的影响分析[J].中国医药科学,2018,8(18):46-49.
[15] 李万光.类风湿性关节炎的中医辨治体会[J].中医临床研究,2016,8(10):39-41.
[16] 卓和伟,章磊.通痹除湿活络汤治疗瘀血痹阻型类风湿关节炎64例[J].浙江中医杂志,2019,54(4):267.
[17] 刘鑫,杨霞芳.高敏C反应蛋白类风湿因子和红细胞沉降率在类风湿性关节炎诊断中的应用探讨[J].基层医学论坛,2016,20(27):3808-3809.
[18] 许丹丹.6种血液指标在类风湿关节炎中的诊断价值[J].检验医学与临床,2018,15(23):3502-3504.
[19] 陈晓宇.血清RF、抗CCP抗体和AFA抗体联合检测在早期诊断类风湿关节炎中的价值[J].中国现代医生,2018, 56(32):1-4.
[20] 陈永,宣亚男,陈艳娟,等.白蛋白/球蛋白与类风湿性关节炎患者的DAS28和ESR的相关性(英文)[J].暨南大学学报:自然科学与医学版,2019,40(5):373-382.
[21] 王静.环磷酰胺冲击联合醋酸泼尼松片对类风湿关节炎患者症状改善及ESR、血清CRP水平的影响[J].首都食品与医药,2019,26(23):100.
[22] 何春辉,姚梓平,马华.化瘀通痹方联合MTX治疗难治性类风湿关节炎的疗效及对RF、CRP和ESR的影响[J].四川中医,2019,37(10):134-137.
[23] 翟天航,张洁,李会丹,等.类风湿性关节炎患者滑膜组织中HIF-1α与MMPs相关性研究[J].上海交通大学学报:医学版,2015,35(9):1248-1251.
[24] 徐丹,高明利,于静,等.中西医结合治疗类风湿性关节炎的疗效[J].世界中医药,2018,13(1):83-87.
[25] 马风英.仙灵骨葆胶囊联合甲氨蝶呤治疗类风湿性关节炎继发骨质疏松症37例[J].西部中医药,2018,31(2):98-100.
[26] 朱蕾,李娟,武丹威,等.羧胺三唑对TNF-α诱导的成纤维样滑膜细胞增殖及MMP-1、MMP-3表达的影响[J].中华临床医师杂志:电子版,2013,7(10):4354-4357.
[27] 朱波,杨艳,苏仁意,等.桂枝芍药知母汤加减治疗类风湿性关节炎的疗效及其对程序性死亡分子配体-1表达的影响[J].世界中医药,2019,14(7):1728-1732.
[28] Klimiuk PA,Domys?覥awska I,Sierakowski S,et al. Regulation of serum matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 following rituximab therapy in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor blockers [J]. Rheumatol Int,2015,35(4):749-755. |
|
|
|